PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis

NYSE:MD • US58502B1061

18.82 USD
-0.48 (-2.49%)
At close: Feb 20, 2026
18.4 USD
-0.42 (-2.23%)
After Hours: 2/20/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

MD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD is valued quite cheap, but it does not seem to be growing. These ratings could make MD a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year MD was profitable.
  • MD had a positive operating cash flow in the past year.
  • In multiple years MD reported negative net income over the last 5 years.
  • Of the past 5 years MD 4 years had a positive operating cash flow.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • MD has a better Return On Assets (7.37%) than 89.22% of its industry peers.
  • The Return On Equity of MD (18.21%) is better than 86.27% of its industry peers.
  • With an excellent Return On Invested Capital value of 10.25%, MD belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
  • MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.00%.
  • The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROIC 10.25%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Profit Margin value of 8.44%, MD belongs to the best of the industry, outperforming 89.22% of the companies in the same industry.
  • MD has a better Operating Margin (12.20%) than 83.33% of its industry peers.
  • In the last couple of years the Operating Margin of MD has declined.
Industry RankSector Rank
OM 12.2%
PM (TTM) 8.44%
GM N/A
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
  • MD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.09. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • MD's Altman-Z score of 2.09 is in line compared to the rest of the industry. MD outperforms 51.96% of its industry peers.
  • The Debt to FCF ratio of MD is 2.20, which is a good value as it means it would take MD, 2.20 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.20, MD is doing good in the industry, outperforming 76.47% of the companies in the same industry.
  • A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.65, MD is in line with its industry, outperforming 55.88% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Altman-Z 2.09
ROIC/WACC1.21
WACC8.47%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
  • MD has a Current ratio of 1.83. This is in the better half of the industry: MD outperforms 72.55% of its industry peers.
  • MD has a Quick Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • MD has a Quick ratio of 1.83. This is in the better half of the industry: MD outperforms 74.51% of its industry peers.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
  • The Earnings Per Share has been growing by 10.01% on average over the past years. This is quite good.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 1.48% on average over the next years.
  • MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.60% yearly.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.27, the valuation of MD can be described as very reasonable.
  • 94.12% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, MD is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 8.35, the valuation of MD can be described as reasonable.
  • 94.12% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
  • MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.27
Fwd PE 8.35
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 88.24% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
  • MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 91.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.91
EV/EBITDA 6.5
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.84
PEG (5Y)0.93
EPS Next 2Y8.08%
EPS Next 3Y2.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (2/20/2026, 8:04:00 PM)

After market: 18.4 -0.42 (-2.23%)

18.82

-0.48 (-2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners98.9%
Inst Owner Change-0.24%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.62B
Revenue(TTM)N/A
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (22.85%)
Short Float %3.33%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 9.27
Fwd PE 8.35
P/S 0.84
P/FCF 5.91
P/OCF 5.57
P/B 1.81
P/tB N/A
EV/EBITDA 6.5
EPS(TTM)2.03
EY10.79%
EPS(NY)2.25
Fwd EY11.97%
FCF(TTM)3.18
FCFY16.91%
OCF(TTM)3.38
OCFY17.94%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.84
PEG (5Y)0.93
Graham Number21.76
Profitability
Industry RankSector Rank
ROA 7.37%
ROE 18.21%
ROCE 12.98%
ROIC 10.25%
ROICexc 13.79%
ROICexgc 251.95%
OM 12.2%
PM (TTM) 8.44%
GM N/A
FCFM 14.22%
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.2
Debt/EBITDA 2.24
Cap/Depr 72.01%
Cap/Sales 0.86%
Interest Coverage 250
Cash Conversion 112.59%
Profit Quality 168.57%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 2.09
F-Score8
WACC8.47%
ROIC/WACC1.21
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 5 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.27 and the Price/Book (PB) ratio is 1.81.